By InvitationEarly Phase 1

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

United States20 participantsStarted 2023-09-17

Plain-language summary

The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Planning to undergo transplantation of the lung at Northwestern Memorial Hospital. * Willing and able to read, understand, and be capable of giving informed consent. Exclusion Criteria: * Previous or current use of TNFa antibody. * Positive virtual or retrospective crossmatch or highly sensitized (pRA \> 30%) recipients. * Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating.

What they're measuring

Occurrence of kidney dysfunction immediately after lung transplant

Timeframe: Immediately after lung transplant

Occurrence of kidney dysfunction post-operatively within 1 week after lung transplant

Timeframe: Within 1-7 days after lung transplant

Occurrence of kidney dysfunction post-operatively within 1 month after lung transplant

Timeframe: Up to 30 days after lung transplant

Trial details

NCT IDNCT05950724

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Lung Transplant; Complications trials